Evidence map›Paper›PMID 34061203›Full record

ArticleJAMA network open2021

Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality.

Mehul D Patel, Erik Rosenstrom, Julie S Ivy, Maria E Mayorga, Pinar Keskinocak, Ross M Boyce, Kristen Hassmiller Lich, Raymond L Smith, Karl T Johnson, Paul L Delamater and 1 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Comparative evaluation of behavioral epidemic models using COVID-19 data.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Mehul D PatelDepartment of Emergency Medicine, School of Medicine, University of North Carolina at Chapel Hill.
Erik RosenstromDepartment of Industrial and Systems Engineering, North Carolina State University, Raleigh.
Julie S IvyDepartment of Industrial and Systems Engineering, North Carolina State University, Raleigh.
Maria E MayorgaDepartment of Industrial and Systems Engineering, North Carolina State University, Raleigh.
Pinar KeskinocakDepartment of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta.
Ross M BoyceDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill.
Kristen Hassmiller LichDepartment of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.
Raymond L SmithDepartment of Engineering, College of Engineering and Technology, East Carolina University, Greenville, North Carolina.
Karl T JohnsonDepartment of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill.
Paul L DelamaterDepartment of Geography, College of Arts and Sciences, University of North Carolina at Chapel Hill.
Julie L SwannDepartment of Industrial and Systems Engineering, North Carolina State University, Raleigh.
University of North Carolina at Chapel Hill · USNorth Carolina State University · USEast Carolina University · USGeorgia Institute of Technology · US

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
North Carolina Translational and Clinical Science Institute (NC TraCS) KL2KL2TR002490 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WEINBERGER, MORRIS · 2018 to 2022
$11.0M
Understanding the relationship between herd immunity and geographic scale to improve estimates of localized infectious disease outbreak riskK01AI151197 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DELAMATER, PAUL · 2020 to 2023
$544k
NCATS NIH HHS KL2 TR002490NCATS NIH HHS UL1 TR002489NIAID NIH HHS K01 AI151197
6 · The paper itself

Abstract

Importance: Vaccination against SARS-CoV-2 has the potential to significantly reduce transmission and COVID-19 morbidity and mortality. The relative importance of vaccination strategies and nonpharmaceutical interventions (NPIs) is not well understood. Objective: To assess the association of simulated COVID-19 vaccine efficacy and coverage scenarios with and without NPIs with infections, hospitalizations, and deaths. Design, Setting, and Participants: An established agent-based decision analytical model was used to simulate COVID-19 transmission and progression from March 24, 2020, to September 23, 2021. The model simulated COVID-19 spread in North Carolina, a US state of 10.5 million people. A network of 1 017 720 agents was constructed from US Census data to represent the statewide population. Exposures: Scenarios of vaccine efficacy (50% and 90%), vaccine coverage (25%, 50%, and 75% at the end of a 6-month distribution period), and NPIs (reduced mobility, school closings, and use of face masks) maintained and removed during vaccine distribution. Main Outcomes and Measures: Risks of infection from the start of vaccine distribution and risk differences comparing scenarios. Outcome means and SDs were calculated across replications. Results: In the worst-case vaccination scenario (50% efficacy, 25% coverage), a mean (SD) of 2 231 134 (117 867) new infections occurred after vaccination began with NPIs removed, and a mean (SD) of 799 949 (60 279) new infections occurred with NPIs maintained during 11 months. In contrast, in the best-case scenario (90% efficacy, 75% coverage), a mean (SD) of 527 409 (40 637) new infections occurred with NPIs removed and a mean (SD) of 450 575 (32 716) new infections occurred with NPIs maintained. With NPIs removed, lower efficacy (50%) and higher coverage (75%) reduced infection risk by a greater magnitude than higher efficacy (90%) and lower coverage (25%) compared with the worst-case scenario (mean [SD] absolute risk reduction, 13% [1%] and 8% [1%], respectively). Conclusions and Relevance: Simulation outcomes suggest that removing NPIs while vaccines are distributed may result in substantial increases in infections, hospitalizations, and deaths. Furthermore, as NPIs are removed, higher vaccination coverage with less efficacious vaccines can contribute to a larger reduction in risk of SARS-CoV-2 infection compared with more efficacious vaccines at lower coverage. These findings highlight the need for well-resourced and coordinated efforts to achieve high vaccine coverage and continued adherence to NPIs before many prepandemic activities can be resumed.

Indexed as

Communicable Disease ControlCOVID-19Mass VaccinationVaccination CoverageAdultComputer SimulationCOVID-19 VaccinesDisease Transmission, InfectiousFemaleHospitalizationHumansMaleMortalityNorth CarolinaRisk AssessmentSARS-CoV-2COVID-19 Vaccines

Identifiers

PMID34061203
PMCPMC8170542
OpenAlexW3164626794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.